About

About CURAVAC EUROPE CuraVac is an innovative clinical stage company developing therapeutic vaccines to bring long lasting improvement to patients by addressing the root cause of autoimmune diseases. About CURAVAC EUROPE CuraVac is an innovative clinical stage company developing therapeutic vaccines to bring long lasting improvement to patients by addressing the root cause of autoimmune diseases. CuraVac is a Belgian clinical-stage biotech developing Targeted Active Therapy (TAT) to neutralize harmful autoantibodies while preserving the immune system. Its lead candidate, CV-MG02, targets Myasthenia Gravis (MG), showing a strong safety profile and early efficacy in Phase 1. CuraVac is advancing an improved formulation to Phase 2 and expanding its platform to other autoimmune diseases, including MS, type 1 diabetes, SLE, Hashimoto’s disease, and Graves' disease. CuraVac’s CV-MG02 is a Targeted Active Therapy (TAT) for Myasthenia Gravis (MG) that neutralizes disease-causing autoantibodies while preserving the immune system. Based on peptide antigens designed to induce the production of specific anti-autoantibodies that counteract autoimmune attack on the neuromuscular junction, CV-MG02 offers long-term efficacy with minimal dosing, reducing reliance on lifelong immunosuppression. Early trials showed a strong safety profile and sustained remission in some patients for years.